First Custom CRISPR Therapy for Ultra-Rare Disease Thrives After One Year
Key Questions
What is the current status of the child who received the custom CRISPR therapy?
The child with CPS1 deficiency is thriving one year after receiving three doses of a personalized CRISPR base-editing therapy at Children’s Hospital. This outcome demonstrates the potential of custom gene editing for ultra-rare diseases.
How does this case illustrate regulatory changes for personalized gene therapies?
The therapy highlights the FDA's Plausible Mechanism framework and shifts toward supporting rapid development of individualized treatments. It shows feasibility for quick manufacturing in rare disease contexts.
What broader implications does this have for ultra-rare diseases?
The success points to expanded use of personalized CRISPR editing for conditions previously lacking targeted options. It underscores regulatory and technical advances enabling such therapies.
A child with CPS1 deficiency treated with a personalized CRISPR therapy is thriving a year later. The case highlights regulatory shifts (FDA's Plausible Mechanism framework), rapid manufacturing, and the potential for personalized gene editing in ultra-rare diseases.